从肝切除术的角度优化BCLC B期HCC的再分期

发布时间：2022-01-10 16:57

　　前言近些年来,肝细胞癌（hepatocellular carcinoma,HCC）发病率在局部地区有上升趋势,是全球第三大癌症死因。世界上约75%-80%的HCC患者为亚太居民,这些患者HCC多由于HBV和/或HCV导致的肝硬化所致。中国大陆HCC患者众多,每年发病率约为28/10万,死亡率为26/10万。而且,HCC起病隐匿,患者就诊时病情多已属中晚期,患者长期预后差。HCC肿瘤分期决定着患者的治疗方式和远期疗效。巴塞罗那肝癌分期系统（Barcelona Clinical Liver Cancer,BCLC）备受国内外学者推崇,是唯一被美国肝病研究协会（American Association for the Study of Liver Diseases,AASLD）和欧洲肝脏研究协会（European Association for the Study of the Liver,EASL）双重推荐的HCC分期系统。BCLC分期系统仅推荐A期HCC患者行肝切除术,患者应符合Milan标准:（a）仅有单个肿瘤且肿瘤直径<5cm,或≤3个结节,且最大肿瘤直径≤3cm;（b）肝功能... 

【文章来源】：广西医科大学广西壮族自治区

【文章页数】：116 页

【学位级别】：博士

【部分图文】：

大/多结节HCC患者行肝切除术后5年总生存率和无病生存率

患者术后 5 年总生存率和无瘤生存率均随年份显著提高（P<0.001，图 1-2和图 1-3）。图1-2. 大/多结节HCC 患者行肝切除术后 5年总生存率随时间变化情况Fig 1-2. Five-year survival trend of patients with large/multinodular hepatocellular carcinoma after surgery图1-3. 大/多结节HCC 患者行肝切除术后 5年无病生存率随时间变化情况Fig 1-3. Five-year disease-free survival trend of patients with large/multinodular hepatocellular carcinomaafter surgery

图1-2. 大/多结节HCC 患者行肝切除术后 5年总生存率随时间变化情况Fig 1-2. Five-year survival trend of patients with large/multinodular hepatocellular carcinoma after surgery图1-3. 大/多结节HCC 患者行肝切除术后 5年无病生存率随时间变化情况Fig 1-3. Five-year disease-free survival trend of patients with large/multinodular hepatocellular carcinomaafter surgery

【参考文献】：
期刊论文
[1]肝细胞癌肝切除术的争议[J]. 钟鉴宏,游雪梅,黎乐群.  中国普通外科杂志. 2017(01)
[2]肝切除术治疗大/多结节或大血管侵犯肝细胞癌效果的荟萃分析[J]. 李威,游雪梅,黎乐群,钟鉴宏.  中华医学杂志. 2015 (38)
[3]肝细胞癌根治性术后的治疗选择[J]. 钟鉴宏,黎乐群.  中华临床医师杂志(电子版). 2013(23)
[4]Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy[J]. Yang Ke,Liang Ma,Xue-Mei You,Sheng-Xin Huang,Yong-Rong Liang,Bang-De Xiang,Le-Qun Li.  Cancer Biology & Medicine. 2013(03)
[5]Report of incidence and mortality in China cancer registries, 2009[J]. Wanqing Chen,Rongshou Zheng,Siwei Zhang,Ping Zhao,Guanglin Li,Lingyou Wu,Jie He.  Chinese Journal of Cancer Research. 2013(01)
[6]Role of surgical resection for multiple hepatocellular carcinomas[J]. Sung Hoon Choi,Gi Hong Choi,Seung Up Kim,Jun Yong Park,Dong Jin Joo,Man Ki Ju,Myoung Soo Kim,Jin Sub Choi,Kwang Hyub Han,Soon Il Kim.  World Journal of Gastroenterology. 2013(03)
[7]原发性肝癌诊疗规范（2011年版）[J]. Ministry of Health of the People’s Republic of China.  临床肝胆病杂志. 2011(11)
[8]Therapeutic options for intermediate-advanced hepatocellular carcinoma[J]. Zong-Ming Zhang, Jin-Xing Guo, Zi-Chao Zhang, Nan Jiang, Zhen-Ya Zhang, Li-Jie Pan, Department of General Surgery, Digestive Medical Center, The First Affiliated Hospital, School of Medicine, Tsinghua University, Beijing 100016, China.  World Journal of Gastroenterology. 2011(13)
[9]Hepatectomy in the treatment of very big primary liver cancer: report of 86 cases[J]. Jia-Mei Yang;Tong Kan;Han Chen;Meng-Chao Wu From the Eastern Hospital of Hepatobiliary Surgery, Second Military Medical University, Shanghai 200433 China.  Hepatobiliary & Pancreatic Diseases International. 2002(01)
[10]Stage Ⅱ surgical resection of hepatocellular carcinoma after TAE:a report of 38 cases[J]. WANG Jian Hua, LIN Gui △, YAN Zhi Ping, WANG Xiao Lin, CHENG Jie Ming and LI Mao Quan.  World Journal of Gastroenterology. 1998(02)



本文编号：3581066